Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly › Eli Lilly (NYSE: LLY) has been a terrific stock to own over the past 15 years; it has consistently outperformed ...

U.S. pharma bounced back in Q2, and in this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy ...

New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

If approved, AbbVie's Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than main ...

According to a report by the Financial Times, Morgan & Morgan, a law firm, revealed it had filed a case on behalf of a ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly increasing it, new findings suggest.

Eli Lilly and Company faces a pivotal period with the upcoming retirement of Anne White, a key neuroscience leader set for ...

J&J said on Thursday it has reached a 10-year agreement with Tokyo-based contract drug developer Fujifilm Biotechnologies for ...

With the cost of the weight-loss jab set to rise by up to 170 per cent, Jade Kay, who has already spent £2,400 on the drug, says she will take a second job waitressing if she has to ...

Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...

S&P 500, Eli Lilly and Company, Nomura Holdings Inc ADR, The Health Care Select Sector SPDR® Fund. Read 's Market Analysis on Investing.com ...